Clinical setbacks and controversial pricing may have put a dampener on the gene therapy sector, but one of the industry’s pioneers is looking for a way forward.

GEMMA Biotherapeutics, the biotech founded by gene therapy trailblazer James Wilson M.D., Ph.D., has launched a clinical-stage spinout focused specifically on ultra-orphan diseases.